Consumer medicine information

Combivir

Lamivudine + Zidovudine

BRAND INFORMATION

Brand name

Combivir

Active ingredient

Lamivudine + Zidovudine

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Combivir.

COMBIVIR

COMBIVIR


 Consumer Medicine Information (CMI) summary

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.


 1. Why am I taking COMBIVIR?

COMBIVIR contains the active ingredients lamivudine and zidovudine. COMBIVIR is used, alone or in combination with other antiretrovirals, to slow down the progression of human immunodeficiency virus (HIV) infection which can lead to Acquired Immune Deficiency Syndrome (AIDS) and other related illnesses (e.g. AIDS-related Complex (ARC)).

For more information, see Section 1. Why am I taking COMBIVIR? in the full CMI.

 2. What should I know before I take COMBIVIR?

Do not use if you have ever had an allergic reaction to COMBIVIR or any of the ingredients listed at the end of the CMI.

Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.

For more information, see Section 2. What should I know before I take COMBIVIR? in the full CMI.

 3. What if I am taking other medicines?

Some medicines may interfere with COMBIVIR and affect how it works.

A list of these medicines is in Section 3. What if I am taking other medicines? in the full CMI.

 4. How do I take COMBIVIR?
  • The usual dosage of COMBIVIR is one tablet twice a day.
  • Swallow the tablet whole with a glass of water.

More instructions can be found in Section 4. How do I take COMBIVIR? in the full CMI.

 5. What should I know while taking COMBIVIR?

Things you should do
  • Remind any doctor, dentist or pharmacist you visit that you are taking COMBIVIR.
  • For as long as you are taking COMBIVIR, your doctor will arrange for you to have regular blood tests to check for side effects.
Things you should not do
  • Do not stop using this medicine suddenly or change the dose without talking to your doctor.
  • Do not take this medicine to treat any other complaints.
  • Do not give this medicine to children under the age of 12.
Driving or using machines
  • Be careful before you drive or use any machines or tools until you know how COMBIVIR affects you.
  • COMBIVIR may cause headache and tiredness in some people.
Looking after your medicine
  • Store COMBIVIR below 30°C in the pack.
  • Keep this medicine in the pack until it is time to take it.

For more information, see Section 5. What should I know while taking COMBIVIR? in the full CMI.

 6. Are there any side effects?

Side effects that have been reported include sweating, body odour, chills, swelling of the lips/tongue, flu-like symptoms, fever, increased sensitivity to pain, back pain, enlarged glands, chest pain, weakness, weight loss, loss of appetite, vomiting or nausea, generally feeling unwell, breast enlargement in men, widening of blood vessels leading to low blood pressure and feeling faint, fainting, constipation, gas from the stomach or bowel, blood in the stool, diarrhoea, difficulty in swallowing, mouth ulcers, bleeding gums, heartburn, abdominal discomfort or pain, muscle aches or pains, muscle shaking or spasm or twitching, muscle disease, enlarged fatty liver, abnormal results of liver function blood tests, confusion, depression, nervousness, loss of mental clarity, dizziness, headaches, sleeplessness, fatigue or tiredness, cough, sore throat, hay fever, sinus problems, hoarseness, changes to perception of taste, acne, itchiness, skin rash, changes in nail, skin or mouth colour, vision problems, sensitivity to light, hearing loss, passing too much urine or increased frequency of urination, increased bruising or bleeding, hair loss.
For more information, including what to do if you have any side effects, see Section 6. Are there any side effects? in the full CMI.


COMBIVIR

Active ingredients: lamivudine and zidovudine


 Consumer Medicine Information (CMI)

This leaflet provides important information about using COMBIVIR. You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using COMBIVIR.

Where to find information in this leaflet:

1. Why am I taking COMBIVIR?
2. What should I know before I take COMBIVIR?
3. What if I am taking other medicines?
4. How do I take COMBIVIR?
5. What should I know while taking COMBIVIR?
6. Are there any side effects?
7. Product details

1. Why am I taking COMBIVIR?

COMBIVIR contains the active ingredients lamivudine and zidovudine.

COMBIVIR belongs to a group of medicines known as antiretrovirals.

COMBIVIR is used, alone or in combination with other antiretrovirals, to slow down the progression of human immunodeficiency virus (HIV) infection which can lead to Acquired Immune Deficiency Syndrome (AIDS) and other related illnesses (e.g. AIDS-related Complex (ARC)).

COMBIVIR does not cure AIDS or HIV infection however it slows down production of HIV in the body. In this way it stops ongoing damage to the body's immune system which fights infection.

You can still pass on HIV when taking this medicine through sexual activity or through passing on blood or bodily secretions which carry the HIV virus, although the risk is lowered by taking antiretroviral therapy.

You should use proper precautions to prevent this from occurring. Discuss with your doctor the precautions needed to avoid infecting other people.

While taking COMBIVIR and/or any other therapy for HIV, you may continue to develop other infections and other complications of HIV infection. You should keep in regular contact with your doctor.

The active ingredients in COMBIVIR are available separately. Lamivudine is available under the brand name 3TC (tablets and oral solution) and zidovudine is available under the brand name Retrovir (capsules and oral solution).

2. What should I know before I take COMBIVIR?

Warnings

Do not use COMBIVIR if:

  • you are allergic to lamivudine, zidovudine or any of the ingredients listed at the end of this leaflet.

Always check the ingredients to make sure you can use this medicine.

  • you have kidney or liver disease
  • you have a reduced red blood cell count (anaemia) or white blood cell count (neutropenia)
  • are pregnant, trying to become pregnant or breastfeeding

Check with your doctor if you:

  • have any other medical conditions
  • have or have had hepatitis B

If you have a long-standing viral infection of your liver (hepatitis B) it may flare up. This can cause serious illness particularly if your liver is already not working very well. If you have both HIV and hepatitis B, when you stop taking COMBIVIR your doctor is likely to arrange tests from time to time to check how well your liver is working and to measure virus levels.

  • take any medicines for any other condition
  • are allergic to any other foods, dyes, preservatives or any other medicines

During treatment, you may be at risk of developing certain side effects. It is important you understand these risks and how to monitor for them. See additional information under Section 6. Are there any side effects?

Pregnancy and breastfeeding

Talk to your doctor if you are pregnant or intend to become pregnant.

Talk to your doctor if you are breastfeeding or intend to breastfeed.

Your doctor can discuss with you the benefits and risks of taking COMBIVIR whilst pregnant or breastfeeding.

Symptoms of infection and inflammation

People with advanced HIV infection (AIDS) have weak immune systems and are more likely to develop serious infections (opportunistic infections). When they start treatment, the immune system becomes stronger and so the body starts to fight infections.

Symptoms of infection and inflammation may develop, caused by either:

  • old, hidden infections flaring up at the body fights them
  • the immune system attacking healthy body tissue (autoimmune disorders)

The symptoms of autoimmune disorders may develop many months after you start taking medications to treat your HIV infection.

Symptoms may include:

  • muscle weakness and/or muscle pain
  • joint pain or swelling
  • weakness beginning in the hands or feet and moving towards the trunk of the body
  • palpitations or tremor
  • hyperactivity (excessive restlessness and movement)

If you get symptoms of infection or if you notice any of the symptoms above, tell your doctor immediately. Do not take other medicines for the infection without your doctor's advice.

Children and adolescents

COMBIVIR is not recommended for use in children under 12 years of age. COMBIVIR is a fixed dose combination tablet and as such it cannot be adjusted according to the size and weight of the patient.

3. What if I am taking other medicines?

Tell your doctor or pharmacist if you are taking any other medicines, including any medicines, vitamins or supplements that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines may interfere with COMBIVIR and affect how it works.

If you take ribavirin (e.g. Ibavyr) and COMBIVIR together it may cause or worsen anaemia (low red blood cells). Tell your doctor if you notice symptoms of anaemia such as tiredness and shortness of breath.

Tell your doctor or pharmacist if you are taking any of the medicines below:

  • paracetamol, a medicine used to treat pain
  • other medicines used to treat pain such as aspirin, codeine, morphine, methadone, indometacin, ketoprofen, naproxen
  • ribavirin
  • medicines used in epilepsy including phenytoin
  • medicines used to treat anxiety and insomnia including oxazepam, lorazepam
  • rifampicin, a medicine used to treat tuberculosis
  • cimetidine, a medicine used to treat heartburn, stomach ulcers
  • clofibrate, a medicine used to treat high cholesterol, high triglycerides
  • probenecid, a medicine used in the treatment of gout
  • antimicrobial medicines such as pentamidine, atovaquone
  • medicines used to treat parasite infections including pyrimethamine, dapsone
  • amphotericin, flucytosine, medicines used to treat fungal infections
  • other antiviral medicines such as aciclovir, ganciclovir, interferon, inosine pranobex, stavudine, zalcitabine, emtricibine
  • clarithromycin, sulfamethoxazole, trimethoprim and ciprofloxacin, antibacterial medicines
  • medicines used in the treatment of cancer including vincristine, vinblastine and doxorubicin
  • sorbitol-containing medicines (usually liquids) which are used regularly

COMBIVIR should not be taken with stavudine or zalcitabine.

Check with your doctor or pharmacist if you are not sure about what medicines, vitamins or supplements you are taking and if these affect COMBIVIR.

4. How do I take COMBIVIR?

How much to take

  • The usual dosage of COMBIVIR is one tablet twice a day
  • Follow the instructions provided and use COMBIVIR until your doctor tells you to stop.

When to take COMBIVIR

  • Your doctor or pharmacist will tell you when to take COMBIVIR each day.

How to take COMBIVIR

  • Swallow the tablet whole with a drink of water.
  • Do not halve the tablet.

If you forget to take COMBIVIR

COMBIVIR should be taken regularly at the same time each day.

If it is almost time for your next dose, skip the dose you missed and take your next dose when you are meant to. Otherwise, take it as soon as you remember and then go back to taking your medicine as you would normally.

Do not take a double dose to make up for the dose you missed.

If you take too much COMBIVIR

If you think that you have used too much COMBIVIR, you may need urgent medical attention.

You should immediately:

  • phone the Poisons Information Centre
    (by calling 13 11 26), or
  • contact your doctor, or
  • go to the Emergency Department at your nearest hospital.

You should do this even if there are no signs of discomfort or poisoning.

5. What should I know while taking COMBIVIR?

Things you should do

Ensure you have blood tests when you are meant to. It is important that your doctor monitors your health and checks the levels of red and white blood cells. If you develop anaemia or neutropenia your doctor may reduce your dose or stop COMBIVIR.

Tell your doctor straight away if you:

  • become pregnant or intend to become pregnant
  • have not taking COMBIVIR as intended

Remind any doctor, dentist or pharmacist you visit that you are taking COMBIVIR.

This is especially important for any medicines that might have an effect on your liver, kidneys, red or white blood cells or other cells in the body.

Things you should not do

  • Do not stop using this medicine or change the dose.
  • Do not give this medicine to anyone else, even if their symptoms seem similar to yours.
  • Do not use this medicine to treat any other complaints unless your doctor tells you to.
  • Do not give this medicine to children under the age of 12.

Stay in regular contact with your doctor

COMBIVIR helps to control your condition, but it is not a cure for HIV infection. You need to keep taking it everyday to stop your illness from getting worse. Because COMBIVIR does not cure HIV infections, you may still develop other infections and illnesses linked to HIV.

Driving or using machines

Be careful before you drive or use any machines or tools until you know how COMBIVIR affects you.

COMBIVIR may cause headache and tiredness in some people.

Looking after your medicine

Follow the instructions on the pack on how to take care of your medicine properly.

Store it in a cool dry place (below 30°C) away from moisture, heat or sunlight; for example, do not store it:

  • in the bathroom or near a sink, or
  • in the car or on window sills.

Keep it where young children cannot reach it.

Getting rid of any unwanted medicine

If you no longer need to use this medicine or it is out of date, take it to any pharmacy for safe disposal.

Do not use this medicine after the expiry date.

6. Are there any side effects?

All medicines can have side effects. If you do experience any side effects, most of them are minor and temporary. However, some side effects may need medical attention.

Within the first few weeks of treatment with anti-HIV medicines, some people, particularly those that have been HIV positive for some time, may develop inflammatory reactions (e.g. pain, redness, swelling, high temperature) which may resemble an infection and may be severe. It is thought that these reactions are caused by a recovery in the body's ability to fight infections, previously suppressed by HIV.

If you become concerned about any new symptoms, or any changes in your health after starting HIV treatment, discuss with your doctor immediately.

See the information below and, if you need to, ask your doctor or pharmacist if you have any further questions about side effects.

Less serious side effects

Less serious side effectsWhat to do
Psychiatric disorders:
  • confusion, depression, nervousness, loss of mental clarity
Nervous system disorders:
  • dizziness, seizures, severe headaches
  • unusual feelings in any part of the body, such as numbness, burning, tingling or pins and needles
  • vision problems, sensitivity to light
Gastrointestinal disorders:
  • constipation, gas from the stomach or bowel, blood in the stool, diarrhoea, abdominal pain
  • vomiting or nausea
  • difficulty in swallowing, mouth ulcers, bleeding gums
  • heartburn
Skin disorders:
  • acne, itchiness, skin rash, changes in nail, skin or mouth colour
Metabolic disorders:
  • weight loss, loss of appetite
Respiratory disorders:
  • cough, sore throat, hay fever, sinus problems, hoarseness, changes to perception of taste
Blood system disorders:
  • widening of blood vessels leading to low blood pressure and feeling faint, fainting
  • increased bruising or bleeding
Musculoskeletal disorders:
  • muscle aches or pains, muscle shaking or spasm or twitching, muscle disease
Urinary disorders:
  • passing too much urine or increased frequency of urination
General disorders:
  • generally feeling unwell
  • flu-like symptoms, fever, sweating, chills
  • weakness, sleeplessness, fatigue or tiredness
  • increased sensitivity to pain, back pain, enlarged glands, chest pain
Side effects that may show up in blood tests:
  • abnormal results of liver function blood tests
Other:
  • body odour
  • hair loss
  • hearing loss
  • swelling of the lips/tongue
  • breast enlargement in men
Speak to your doctor if you have any of these less serious side effects and they worry you.

Serious side effects

Serious side effectsWhat to do
Blood system disorders:
  • reduced red blood cell count (anaemia)
  • reduced white blood cell count (neutropenia)

The frequency and severity of anaemia and neutropenia are greater in patients with advanced HIV disease or in patients who start taking COMBIVIR in the later stages of HIV disease.
Allergic reactions:

  • swelling of the lips, tongue, wheezing or difficulty breathing, rash, hives on the skin. These are all signs of an allergic reaction
Pancreatitis:
  • signs of an inflamed pancreas (pancreatitis) such as severe stomach pain or cramps, nausea, vomiting

If you experience any of these symptoms soon after starting treatment with COMBIVIR stop taking this medicine and contact your doctor immediately.
Change in body shape:
Treatment with COMBIVIR may cause a loss of fat from the legs, arms and face (lipoatrophy). If this occurs tell your doctor and they will assess if you should stop taking COMBIVIR and your HIV treatment be changed. If you stop taking T COMBIVIR it may take several months to see any lost fat return and you might not regain it all.
Lactic acidosis:
If you are taking medication for HIV and become unwell with fast breathing, stop taking COMBIVIR and talk to your doctor immediately. This might be a condition known as ‘lactic acidosis’. The fast breathing is due to high acid levels in the blood. Your liver may not be working properly and gets big and fatty and can be life threatening. This illness occurs more often in women than men.

Call your doctor straight away, or go straight to the Emergency Department at your nearest hospital if you notice any of these serious side effects.

Tell your doctor or pharmacist if you notice anything else that may be making you feel unwell.

See your doctor if you feel generally unwell with a loss of appetite, nausea, vomiting, itching, yellowness of the skin or eyes or have dark coloured urine.

Other side effects not listed here may occur in some people.

Reporting side effects

After you have received medical advice for any side effects you experience, you can report side effects to the Therapeutic Goods Administration online at www.tga.gov.au/reporting-problems. By reporting side effects, you can help provide more information on the safety of this medicine.

Always make sure you speak to your doctor or pharmacist before you decide to stop taking any of your medicines.

7. Product details

This medicine is only available with a doctor's prescription.

What COMBIVIR contains

Active ingredients
(main ingredient)
lamivudine
zidovudine
Other ingredients
(inactive ingredients)
hypromellose
macrogol
magnesium stearate
microcrystalline cellulose
polysorbate 80
silicon dioxide
sodium starch glycollate
titanium dioxide

Do not take this medicine if you are allergic to any of these ingredients.

What COMBIVIR looks like

COMBIVIR tablets available in bottles are white to off-white, film-coated, capsule-shaped tablets, scored tablet engraved with “GXFC3” on both tablet faces (AUST R 61488). The bottle contains 60 tablets.

COMBIVIR tablets available in blister packs are white to off white film-coated capsule-shaped scored tablets, engraved with “GXFC3” on both tablet faces (AUST R 61489). The blister pack contains 60 tablets.

Not all pack sizes and types may be marketed.

Who distributes COMBIVIR

ViiV Healthcare Pty Ltd
Level 4, 436 Johnson Street
Abbotsford VIC 3067
Australia

Trademarks are owned by or licenced to the ViiV Healthcare group of companies.

© 2023 ViiV Healthcare group of companies or its licensor.

This leaflet was prepared on 7 September 2023.

Version 9.0

Published by MIMS December 2023

BRAND INFORMATION

Brand name

Combivir

Active ingredient

Lamivudine + Zidovudine

Schedule

S4

 

1 Name of Medicine

Lamivudine and zidovudine.

2 Qualitative and Quantitative Composition

Combivir Tablets are a fixed combination product containing lamivudine 150 mg and zidovudine 300 mg in each tablet. Product information for 3TC (tablets and oral solution) and Retrovir (capsules and syrup) contain additional information specific for lamivudine and zidovudine, respectively.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Combivir scored tablets are white to off-white capsule shaped film-coated tablets, engraved with "GXFC3" on both tablet faces.

4 Clinical Particulars

4.9 Overdose

Symptoms and signs. There is no experience of overdosage with Combivir. However, there is limited data available on the consequences of ingestion of acute overdoses of either lamivudine or zidovudine in humans. No specific signs or symptoms have been identified following such overdosage.
Treatment. Patients should be observed closely for evidence of toxicity (see Section 4.8 Adverse Effects (Undesirable Effects)) and given the necessary supportive therapy.
Since lamivudine is dialysable, continuous haemodialysis could be used in the treatment of overdosage, although this has not been studied. Haemodialysis and peritoneal dialysis appear to have a negligible effect on the removal of zidovudine. The primary metabolite, 3-azido-3- deoxy-5-O-β-D-glucopyranuronosyl thymidine (GAZT), appears to be more efficiently removed by haemodialysis than peritoneal dialysis. For more details, physicians should refer to the individual product information for these preparations.
For information on the management of overdose, contact the Poison Information Centre on 131126 (Australia).

5 Pharmacological Properties

5.3 Preclinical Safety Data

Genotoxicity. With zidovudine no evidence of mutagenicity (with or without metabolic activation) was observed in the Salmonella mutagenicity assay. In a mutagenicity assay conducted in L5178Y/TK+/- mouse lymphoma cells, zidovudine was weakly mutagenic in the presence and absence of metabolic activation. In an in vitro cytogenetic study performed in cultured human lymphocytes, zidovudine induced dose related structural chromosomal abnormalities. Zidovudine was clastogenic in in vivo micronucleus tests in rats and mice. Zidovudine gave positive results in an in vitro mammalian cell transformation assay.
Lamivudine was not active in a microbial mutagenicity screen but did induce mutations at the thymidine kinase locus of mouse lymphoma L5178Y cells without metabolic activation. Lamivudine was clastogenic in human peripheral blood lymphocytes in vitro, with or without metabolic activation. In rats, lamivudine did not cause chromosomal damage in bone marrow cells in vivo or cause DNA damage in primary hepatocytes.
No mutagenicity studies have been carried out using a combination of lamivudine and zidovudine.
Carcinogenicity. Zidovudine was administered orally to separate groups of mice and rats at doses up to 40 and 300 mg/kg/day, respectively. In mice, seven late-appearing (after 19 months) vaginal neoplasms (5 non-metastasising squamous cell carcinomas, one squamous cell papilloma, and one squamous polyp) occurred in animals given the highest dose. One late-appearing squamous cell papilloma occurred in the vagina of a middle dose animal. No vaginal tumours were found at the lowest dose. In rats, two late-appearing (after 20 months), non-metastasising vaginal squamous cell carcinomas occurred in animals given the highest dose. No vaginal tumours occurred at the low or middle dose in rats. No other drug related tumours were observed in either sex of either species. At doses that produced tumours in mice and rats, the estimated drug exposure (as measured by AUC) was approximately 4 times (mouse) and 27 times (rat) the estimated human exposure at the recommended therapeutic dose of one tablet twice daily.
When lamivudine was administered orally to separate groups of rodents at doses up to 2000 times (mice and male rats) and 3000 (female rats) mg/kg/day, there was no evidence of a carcinogenic effect due to lamivudine in the mouse study. In the rat study there was an increased incidence of endometrial tumours at the highest dose (approximately 70 times the estimated human exposure at the recommended therapeutic dose of one tablet twice daily, based on AUC). However, the relationship of this increase to treatment is uncertain.
No carcinogenicity studies have been carried out using a combination of lamivudine and zidovudine.

6 Pharmaceutical Particulars

6.7 Physicochemical Properties

Lamivudine is a white to off-white crystalline solid which is highly soluble in water.
Zidovudine is a white to off-white, odourless, crystalline solid.
Lamivudine is the free base of (2R-cis)-4-amino-1-(2-hydroxymethyl- 1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; with a molecular weight of 229.3 and molecular formula C8H11N3O3S.
The chemical name of zidovudine (formerly called azidothymidine (AZT)) is 3'-azido-3'-deoxythymidine; with a molecular weight of 267.24 and molecular formula C10H13N5O4.
Chemical structure. Lamivudine structural formula is shown below:
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSLAMIVU.gif Zidovudine structural formula is shown below:
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSZIDOVU.gif CAS number. 134678-17-4 (lamivudine); 30516-87-1 (zidovudine).

7 Medicine Schedule (Poisons Standard)

Schedule 4 - Prescription Only Medicine.

Summary Table of Changes

https://stagingapi.mims.com/au/public/v2/images/fulltablegif/COMBIVST.gif